Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 24911143)

1.

Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors.

Tanaka M, Yamazaki Y, Kanno Y, Igarashi K, Aisaki K, Kanno J, Nakamura T.

J Clin Invest. 2014 Jul;124(7):3061-74. doi: 10.1172/JCI72399. Epub 2014 Jun 9.

2.

Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma.

Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL.

Cell Cycle. 2006 Dec;5(23):2753-9. Epub 2006 Dec 1.

3.

Promiscuous partnerships in Ewing's sarcoma.

Sankar S, Lessnick SL.

Cancer Genet. 2011 Jul;204(7):351-65. doi: 10.1016/j.cancergen.2011.07.008. Review.

4.

A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.

Leacock SW, Basse AN, Chandler GL, Kirk AM, Rakheja D, Amatruda JF.

Dis Model Mech. 2012 Jan;5(1):95-106. doi: 10.1242/dmm.007401. Epub 2011 Oct 6.

5.

NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.

Kinsey M, Smith R, Lessnick SL.

Mol Cancer Res. 2006 Nov;4(11):851-9.

6.

High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.

Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM.

PLoS One. 2010 Nov 11;5(11):e13943. doi: 10.1371/journal.pone.0013943.

7.

Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.

Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL Jr.

Cancer Res. 2005 Oct 1;65(19):8698-705.

8.

A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature.

Hancock JD, Lessnick SL.

Cell Cycle. 2008 Jan 15;7(2):250-6. Epub 2007 Oct 30.

9.
10.

EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.

Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL.

Cancer Res. 2009 Dec 1;69(23):9047-55. doi: 10.1158/0008-5472.CAN-09-1540. Epub 2009 Nov 17.

11.

An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.

Winter GE, Rix U, Lissat A, Stukalov A, Müllner MK, Bennett KL, Colinge J, Nijman SM, Kubicek S, Kovar H, Kontny U, Superti-Furga G.

Mol Cancer Ther. 2011 Oct;10(10):1846-56. doi: 10.1158/1535-7163.MCT-11-0100. Epub 2011 Jul 18.

12.

Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.

Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslböck M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jürgens H, Kovar H.

J Clin Oncol. 2010 Apr 20;28(12):1982-8. doi: 10.1200/JCO.2009.23.3585. Epub 2010 Mar 22.

13.

[Ewing's tumours, genetic and cellular aspects].

Delattre O.

Pathol Biol (Paris). 2008 Jul;56(5):257-9. doi: 10.1016/j.patbio.2008.03.005. Epub 2008 May 15. French.

PMID:
18485618
14.

Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.

Jully B, Vijayalakshmi R, Gopal G, Sabitha K, Rajkumar T.

BMC Cancer. 2012 Nov 12;12:513. doi: 10.1186/1471-2407-12-513.

15.

Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.

Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, Lessnick SL.

Cancer Cell. 2006 May;9(5):405-16. Erratum in: Cancer Cell. 2007 Jan;11(1):97.

16.

Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).

Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PM.

PLoS One. 2013 Jul 29;8(7):e68985. doi: 10.1371/journal.pone.0068985. Print 2013.

17.

FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.

Yang L, Hu HM, Zielinska-Kwiatkowska A, Chansky HA.

Biochem Biophys Res Commun. 2010 Nov 5;402(1):129-34. doi: 10.1016/j.bbrc.2010.09.129. Epub 2010 Oct 8.

18.

Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.

Boro A, Prêtre K, Rechfeld F, Thalhammer V, Oesch S, Wachtel M, Schäfer BW, Niggli FK.

Int J Cancer. 2012 Nov 1;131(9):2153-64. doi: 10.1002/ijc.27472. Epub 2012 Mar 29.

PMID:
22323082
19.

Loss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis.

Talbot J, Brion R, Picarda G, Amiaud J, Chesneau J, Bougras G, Stresing V, Tirode F, Heymann D, Redini F, Verrecchia F.

Biochim Biophys Acta. 2013 Apr;1832(4):553-64. doi: 10.1016/j.bbadis.2013.01.001. Epub 2013 Jan 9.

20.

The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.

Vural C, Uluoğlu O, Akyürek N, Oğuz A, Karadeniz C.

Pathol Oncol Res. 2011 Sep;17(3):619-25. doi: 10.1007/s12253-010-9358-3. Epub 2011 Jan 26.

PMID:
21267687
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk